Neoantigens are newly formed antigens generated by cancer cells but absent in 12 normal cells. With their high specificity and immunogenicity characteristic, 13 neoantigens are considered as an ideal target for immunotherapy. This study was 14 aimed to investigate the signature of neoantigens in breast cancer. Somatic mutations, 15
Introduction

28
Breast cancer is the world's highest incidence of female malignant tumors, the 29 incidence and mortality rate are ranked in the first female malignant tumors. There 30 were more than two million new cases of breast cancer in 2018, with one in every four 31 cancers of women diagnosed with the disease [1] . Breast cancer is a highly 32 heterogeneous tumor that is currently classified by three molecular markers, including 33 estrogen receptor (ER), progesterone receptor (PR) and HER2 (also called ERBB2), 34 Treatment methods and prognosis of different subtypes of breast cancer vary greatly [2, 35 3] . 36
In recent years, cancer immunotherapy is playing an important role in a variety of 37 solid tumors [4] [5] [6] . The most representative immunotherapy methods are immune 38 checkpoint inhibitors (ICIs), including PD1/ PD-L1 inhibitors, but ICIs are only about 39 30 percent effective. Neoantigen-based immunotherapy is a complement to ICIs 40 therapy, such as neoantigen-based tumor-infiltrating lymphocytes (TILs) therapy in 41 metastatic breast cancer [7] . However, the limitation of neoantigen-based 42 immunotherapy is that different tumor patients have different mutations, and there are 43 fewer neoantigens in common among different tumor patients. T-cell immunotherapy 44 based on KRAS K12D mutation has been reported in colorectal cancer [8] , but similar 45 therapies have not been reported in breast cancer. 46
With the development of sequencing technology, there have been many studies on 47 the mutation characteristics of breast cancer, and a large number of articles based on 48 second-generation sequencing technology have been published [9] [10] [11] [12] . By integrating the 49 clinical information and mutation data of the 8 previous breast cancer research 50 cohorts., we obtained the mutation data of 5991 breast cancer patients [3, [9] [10] [11] [12] [13] . Finally, 51 by combining the high-frequency HLA information and mutation data, we get the 52 most common neoantigens in breast cancer patients, which provides a new road for 53 the neoantigen-based immunotherapy. 54
Results and Discussion
55
The Mutation Landscape of Breast Cancer Patients 56
We have shown the mutation status of all samples in Figure 1 and Figure S1 . 57
Obviously, missense mutation is the main variant classification. At base substitution 58 level, the dominant mutant form is C>T ( Figure S2 ). Besides, the mutation load of 59 each sample is pretty low, with only 25.3 mutations each sample on average and 6 60 mutations for the median. PIK3CA (38%) and TP53 (37%) are two significantly 61 mutated genes, with frequencies much higher than others, such as GATA3 (12%) and 62 CDH1 (12%) ( Figure 1F ). Previous studies have described this high occurrence of 63 PIK3CA and TP53 mutations in breast cancer, although according to which the 64 frequency of TP53 is higher [2, 3, 10, 14, 15] . 65 TP53 and PIK3CA mutations occur frequently no matter in HER2+ or HER2-66 patients. However, the mutated rates are different, for which TP53 (66%) is higher 67 than PIK3CA (32%) in HER2+ patients but conversely in HER2-patients, with 68 mutated rates 33% and 40%, respectively ( Figure S3 -S4). This may indicate its 69 importance on the development and heterogeneity of breast cancer. In further 70 investigation, we identified 22 significantly mutated genes between these two 71 subgroups (Fisher's exact test, P < 0.01, Figure S5 ). A similar result was observed 72 between samples with hormone receptor-positive (HR+) status, defined as PR+ and/or 73 ER+, and HR-status, defined as PR-and ER-( Figure S6 -S8). 74
There are 895 recurrent mutations present in at least 3 patients, comprising 774 75 SNVs, 120 indels and 1 oligo-nucleotide polymorphism (ONP). Mutations after 76 filtering silent variants, coupled with common HLA genotypes, were used for 77 neoantigen prediction. Since previous studies have proved that the common 78 neoantigens may serve as immunotherapy targets [16, 17] , we try to figure out whether 79 there are common neoantigens in breast cancer populations in this way. 80
Results of Neoantigen Prediction 81
Due to the difference between HLA frequency of various populations, 82 high-frequency (> 5%) HLA genotypes were selected from Han Chinese [18] and 83 Americans [19] to predict "public" neoantigens (Table S1) . 84
After filtering, there are 738 non-silent somatic variants, including 617 SNVs 85 and 121 indels, with 356 and 86 derived peptides respectively (Table S2-S3 ). Not all 86 variants exist corresponding neoantigens. Actually, SNV-related neoantigens derived 87 from only 265 variants while 32 variants for indel-related neoantigens. In terms of 88 SNVs, mutations of PIK3CA, AKT1, SF3B1, and ESR1 produce the top 10 89 neoantigens with the highest frequency (Table 1) , especially for PIK3CA, occupying 6 90 of 10. As for indels (Table 2) , although the mutation frequency is lower, the number of 91 neoantigens per mutation is higher, which is 2.69 for each indel but only 1.34 for each 92 SNV on average. 93
Comparison of Neoantigens in Different Subgroups 94
To investigate the relations between clinical information and neoantigens, 95 patients were divided into different subgroups by several clinical indexes. By 96 comparing neoantigens in different subgroups, we found that the elder population 97 (age > 60) carries more SNV-derived neoantigens (Fisher's exact test, P < 0.01, 98 Figure 2A ). As for results of PR or ER status subgroups, patients of positive status 99 tend to produce more SNV-derived neoantigens (Fisher's exact test, P < 0.01, Figure  100 2C-D) than negative ones. On the contrary, neoantigens from SNVs are more 101 produced by HER2-patients ( Figure 2B ). 102
It seems that there is no significant difference in patients in different stages. 103
Although we have observed the difference between patients in Stage I and Stage III 104 (Fisher's exact test, P < 0.01, Figure S9 ), no difference in other stages has reached the 105 significance level. Notably, no matter in which subgroups, SNV-derived neoantigens 106 can cover more patients than indes ( Figure S10 ), suggesting that SNV is the major 107 source of neoantigens in breast cancer patients.
Hotspot Mutations Derived Neoantigens May Serve as Targets of 109
Immunotherapy in Breast Cancer and Pan-cancer 110 H1047R (PIK3CA), E545K (PIK3CA), E17K (AKT1), and N345K (PIK3CA) can 111 produce recurrent neoantigens and have a higher mutation frequency in breast cancer 112 cohort ( Figure 3 ). Thus, we focused on these mutations to investigate the importance 113 of themselves and corresponding neoantigens. 114
In this study, PIK3CA H1047R occurs in 14% of patients in our breast cancer 115 cohort. This is consistent with the result of research by Zehir et al [20] . Besides, Meyer 116 and colleagues demonstrate that this mutation in the luminal mammary epithelium can 117 induce tumorigenesis [21] . In many other cancer types, this mutation also shows a pretty 118 high frequency ( Figure 4A ). The previous study has shown H1047R can be presented 119 by multiple HLA genotypes, such as HLA-C*07:02 and HLA-C*07:01 [16] . These 120 results imply that PIK3CA H1047R may be used as a source of "public" neoantigen in 121 many cancer types. 122 PIK3CA E545K is a hotspot mutation with first-line drugs [22] . In breast cancer, 123 this mutation shows a frequency of about 8%, second to bladder cancer ( Figure 4B ). 124
As for PIK3CA N345K, its mutation frequency is pretty low across all cancers shown 125 in Figure 4D . A case report suggests this mutation might be associated with the 126 sensitivity of Everolimus [23] . 127 AKT1 E17K occurs in many solid tumors with a low frequency ( Figure 4C ). 128
Compared to other AKT1 mutations, E17K shows a much higher occurrence ( Figure  129 3B). In certain breast cancer patients, this mutation is the most likely disease driver [24] . 130
Subsequently, a study demonstrates AKT1 E17K is a therapeutic target in many 131 cancers [25] . 132
Conclusion
133
Based on the analysis of mutation data from eight breast cancer studies, we 134 described the most complete mutation landscape of breast cancer so far. 43 HLA 135 genotypes with high frequency in Chinese or TCGA cohort and 738 non-silent 136 somatic mutations were selected to predict the common neoantigens. The 137 high-frequency mutations, including PIK3CA H1047R (14%), PIK3CA E545K 138 (6.93%), AKT1 E17K (3.27%) and PIK3CA N345K (2.20%), can be recognized by 139 multiple HLA molecules, such as HLA-A1101 and HLA-A03:01. These HLA 140 genotypes are the dominant HLA subtypes in the Han Chinese and Americans, 141
representing the commonality of neoantigens we identified among breast cancer 142 patients. In conclusion, except for having constructed a comprehensive mutation 143 landscape of breast cancer, we also have found a serious of public neoantigens, which 144 may contribute to the development of immunotherapy in breast cancer. 145
Materials and Methods
146
Genomic Data for Breast Cancer Patients 147
All somatic mutations, including single nucleotide variants (SNVs) and short 148 insertion/deletion (indels), were obtained from the published datasets. The data 149 comprises 5991 breast cancer patients from eight studies, covering several important 150 studies, such as The Cancer Genome Atlas Program (TCGA). Clinical information is 151 showed in Table 3 and Table S4 . There is no need for additional informed consent 152 cause all data were from public databases with informed consent provided in the 153 original studies. 154
Neoantigen Prediction 155
Mutations should be non-silent somatic mutations and identified in at least 3 156 breast cancer patients. Subsequently, These mutations, combining with 43 157 high-frequency HLA genotypes in Chinese and TCGA cohorts, were used to predict 158 neoantigens through NetMHC [26] ， NetMHCpan [27] ， PSSMHCpan [28] ， PickPocket [29] 159 and SMM [30] . Criteria for neoantigen screening refer to our previous research [16] . 160
Statistical Analysis 161
We finished all statistical analyses in R-Studio (R version 3.6.0). The two R 162 packages, maftools [31] and ggplot2 [32] , were used for mutations analysis and 163 visualization, respectively. Unless special instruction was given, P < 0. 
